| | | | | | | | The biotechnology company will close its production facilities in Idar-Oberstein, Marburg, and Tübingen in Germany as it looks to optimize capacity. |
|
|
|
| |
| | |
|
|
| | | | Sponsored | | Explore the essential role of precision in pharmaceutical quality control. Learn how lab balances support raw material verification and product formulation. Understand regulatory requirements such as USP Chapters <41> and <1251> and discover strategies to manage sample volumes while maintaining precision. Address data integrity and compliance challenges with Cubis® III balances. |
|
|
|
| |
| | |
|
|
| | | | | The 120,000-square-foot building near Buffalo, New York replaces IMA Life’s existing 60,000-square-foot site to better support biopharmaceutical customers. |
|
|
| The sterile injectable CDMO has entered into a definitive agreement to be purchased by the middle-market private equity firm by the end of the year. |
|
|
| The company has produced its first R&D batches of Exatecan, a starting material, and plans validation batches by year-end, with initial GMP supply targeted for late 2027. |
|
|
|
| |
| | |
|
|
| | | | Sponsored | | The transfer of material into and out of the aseptic core is one of the most critical risk points in any process. Managing that risk to protect product quality and patient safety has historically meant compromising on cost, space and efficiency. Until now. With ChargePoint Actis™ you can achieve isolator-level, Annex 1-aligned regulatory confidence with rapid transfer efficiency and footprint. |
|
|
|
| |
| | |
|
|
| | | | Sponsored | | This webinar will examine how Altruist Biologics’ fully characterized, mature membrane chromatography platform addresses challenges around process robustness, scalability, product quality, and applicability to complex molecules through rapid-cycling, membrane-based purification. |
|
|
|
| |
| | |
|
|
| | |
|
| | |
|
